Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 13,745 matching trials from the live ClinicalTrials.gov search.

Filters: Baltimore, Maryland Clear all

Conditions: Hepatitis C, Chronic
Interventions: Copegus, Pegasys, RO4588161; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 516 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 30
States / cities: Phoenix, Arizona • La Jolla, California • Long Beach, California + 26 more

Conditions: Prostate Cancer
Interventions: 123-I-MIP-1072, 111-In capromab pendetide; Drug
Lead sponsor: Molecular Insight Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 7
States / cities: Laguna Niguel, California • Newport Beach, California • San Francisco, California + 4 more

Conditions: Cystic Fibrosis
Interventions: ELX-02, Ivacaftor; Drug
Lead sponsor: Eloxx Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 7
States / cities: Long Beach, California • Palo Alto, California • Denver, Colorado + 4 more

Conditions: Lung Cancer
Interventions: Pembrolizumab; Drug
Lead sponsor: Canadian Cancer Trials Group; Network
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Chicago, Illinois • Baltimore, Maryland

Conditions: Cytomegalovirus
Interventions: mRNA-1647, Placebo; Biological · Other
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 9 Years to 25 Years
Enrollment: 873 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 44
States / cities: La Mesa, California • Sacramento, California • Fort Collins, Colorado + 38 more

Conditions: Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Margin Squamous Cell Carcinoma, Stage IIB Anal Cancer AJCC v8, Stage III Anal Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Colonoscopy, Computed Tomography, Digital Rectal Examination, High Resolution Anoscopy, Magnetic Resonance Imaging, Nivolumab, Patient Observation, Proctoscopy, Sigmoidoscopy, X-Ray Imaging; Procedure · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 887
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 568 more

Conditions: Low-income Children's Well-child Care Visit
Interventions: Prompting (survey instrument/resources list) (behavior); Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Lung Cancer, Pulmonary Complications, Radiation Fibrosis
Interventions: captopril; Drug
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2016
U.S. locations: 87
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 62 more

Conditions: Restless Legs Syndrome
Interventions: IPX159, Placebo; Drug
Lead sponsor: Impax Laboratories, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 38
States / cities: Brimingham, Alabama • Little Rock, Arkansas • La Jolla, California + 34 more

Conditions: Propionic Acidemia
Interventions: Not listed
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 6
States / cities: Stanford, California • Baltimore, Maryland • Ann Arbor, Michigan + 3 more

Conditions: Macular Degeneration
Interventions: Abicipar Pegol, Ranibizumab, Sham Procedure; Drug · Other
Lead sponsor: Allergan; Industry
Eligibility: 50 Years and older
Enrollment: 949 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 73
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 65 more

Conditions: ESRD, Social Behavior, Physical Disability
Interventions: SOCIABLE; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 60 Years to 100 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Stroke
Interventions: MR-001, Active Walking; Device · Other
Lead sponsor: MedRhythms, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 8
States / cities: Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 5 more

Conditions: Burn Pit Exposure
Interventions: Tele-exercise, Standard of Care; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 40 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Veno-occlusive Disease
Interventions: defibrotide; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: Up to 18 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 9
States / cities: Duarte, California • Baltimore, Maryland • Boston, Massachusetts + 3 more

Conditions: HIV Infections
Interventions: VRC-HIVDNA009-00-VP; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 14
States / cities: Birmingham, Alabama • San Francisco, California • Baltimore, Maryland + 8 more

Conditions: Malignant Salivary Gland Neoplasm, Recurrent Salivary Gland Carcinoma, Salivary Gland Adenoid Cystic Carcinoma, Stage IV Major Salivary Gland Cancer AJCC v7
Interventions: Dasatinib, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 31
States / cities: Beverly Hills, California • Duarte, California • Los Angeles, California + 27 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Atenolol; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 21 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acute Kidney Injury
Interventions: Not listed
Lead sponsor: Abbott RDx Cardiometabolic; Other
Eligibility: 21 Years and older
Enrollment: 1,001 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 25
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 21 more

Conditions: Cystic Fibrosis
Interventions: Ivacaftor, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 39
States / cities: Birmingham, Alabama • Oakland, California • Palo Alto, California + 34 more

Conditions: Early Pregnancy Loss, Delayed Pregnancy Loss
Interventions: CCT-102 A and CCT-102 B; Combination Product
Lead sponsor: Conceptra Biosciences, LLC; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 183 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 15
States / cities: Tucson, Arizona • San Fernando, California • Panama City, Florida + 12 more

Conditions: Cataract, Refractive Error, Low Vision
Interventions: Visual impairment intervention program; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 65 Years and older
Enrollment: 2,544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Sleep Disorder
Interventions: Not listed
Lead sponsor: Itamar-Medical, Israel; Industry
Eligibility: 12 Years to 99 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Baltimore, Maryland • Towson, Maryland

Conditions: Alzheimer's Disease in Down Syndrome
Interventions: Not listed
Lead sponsor: LuMind IDSC Foundation; Other
Eligibility: 35 Years and older
Enrollment: 46 participants
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: San Diego, California • Park Ridge, Illinois • Baltimore, Maryland + 2 more

Search by objective public record fields.

A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.

A Phase I Pilot Study Comparing 123I MIP 1072 Versus 111In Capromab Pendetide in Subjects With Metastatic Prostate Cancer

A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele

Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer

A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

Assisting Low-Income Families at Pediatric Well-Child Care Visits

Captopril in Treating Patients With Non-Small Cell Lung Cancer or Limited-Stage Small Cell Lung Cancer That Has Been Previously Treated With Radiation Therapy With or Without Chemotherapy

Safety and Efficacy Study of IPX159 in Restless Legs Syndrome (RLS)

A Retrospective Study to Characterize Participants With Propionic Acidemia

Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration

SOCIABLE Seniors Optimizing Community Integration to Advance Better Living With ESRD

Post-Stroke Walking Speed and Community Ambulation Conversion Study

Tele-Exercise for MERP

Defibrotide in Treating Patients With Liver Damage Following Peripheral Stem Cell Transplantation

Safety of and Immune Response to an HIV-1 DNA Vaccine (VRC HIVDNA009-00-VP) in HIV Uninfected Adults

Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors

Examining Genetic Influence on Response to Beta-Blocker Medications in People With Type 2 Diabetes

Rapid Evaluation of Acute Kidney Injury With NGAL in Acutely Ill Patients in the ICU

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation

CCT-102 or Expectant Management in Delayed Pregnancy Loss

A Study of Interventions to Reduce Disability From Visual Loss in Nursing Home Residents

A Prospective Study to Evaluate the WP in Comparison to PSG in Patients Suspected of Sleep Disorders

Goal Attainment Scaling (GAS) Sub-Study